Anti-CD19/CD20/CD22 CAR T-Cells for Refractory B-Cell Prolymphocytic Leukemia
Phase-Based Progress Estimates
Ohio State University Comprehensive Cancer Center, Columbus, OH
Refractory B-Cell Prolymphocytic Leukemia+25 More
Anti-CD19/CD20/CD22 CAR T-Cells - Biological
You have a chance of qualifying for this trial. We made sure your application will take less than 5 minutes.
What conditions do you have?
What conditions do you have?
This phase I trial tests the safety, side effects and best infusion dose of genetically engineered cells called anti-CD19/CD20/CD22 chimeric antigen receptor (CAR) T-cells following a short course of chemotherapy with cyclophosphamide and fludarabine in treating patients with lymphoid cancers (malignancies) that have come back (recurrent) or do not respond to treatment (refractory). Lymphoid malignancies eligible for this trial are: non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and B-prolymphocytic leukemia (B-PLL). T-cells (a type of white blood cell) form part of the body's immune system. CAR-T is a type of cell therapy that is used with gene-based therapies. CAR T-cells are made by taking a patient's own T-cells and genetically modifying them with a virus so that they are recognized by a group of proteins called CD19/CD20/CD22 which are found on the surface of cancer cells. Anti-CD19/CD20/CD22 CAR T-cells can recognize CD19/CD20/CD22, bind to the cancer cells and kill them. Giving combination chemotherapy helps prepare the body before CAR T-cell therapy. Giving CAR-T after cyclophosphamide and fludarabine may kill more tumor cells.
Sumithira Vasu, MDPrincipal InvestigatorOhio State University Comprehensive Cancer Center
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
The patient's lymphoid malignancy must be positive for CD19 and/or CD20 and/or CD22, either by immunohistochemistry or flow cytometry analysis on the last biopsy available or peripheral blood for circulating disease.
Subjects with relapsed/refractory B-prolymphocytic leukemia who have received at least 1- 2 prior lines of appropriate therapy and who have failed or are ineligible for allogeneic stem cell transplant are eligible for this study.
Subjects with relapsed/refractory acute B-lymphoblastic leukemia who have received at least 2 prior lines of appropriate therapy or who have failed or are ineligible for allogeneic stem cell transplant.
Patients who received blinatumomab or inotuzumab are eligible.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.